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A B S T R A C T   
NanoLuc luciferase recently gained popularity due to its small size and superior bioluminescence performance. 
For in vivo imaging applications, NanoLuc has been limited by its substrate furimazine, which has low solubility 
and bioavailability. Herein, we compared the performances of recently reported NanoLuc luciferase substrates 
for in vivo imaging in mice. Two substrates with improved aqueous solubility, hydrofurimazine and fluorofur-
imazine, were evaluated along with three stabilized O-acetylated furimazine analogues, the hikarazines. All 5 
analogues, when tested in vitro, displayed greater signal intensity and reaction duration, in comparison to the 
standard NanoLuc substrate, furimazine. The two best-performing analogues from the in vitro study were selected 
for further in vivo testing. The NanoLuc/fluorofurimazine pair demonstrated the highest bioluminescence in-
tensity, post intravenous administration. It was found to be around 9-fold brighter compared to the NanoLuc/ 
furimazine and 11-fold more intense than the NanoLuc/hikarazine-003 pair, with an average of 3-fold higher 
light emission when the substrate was injected intraperitoneally, in a subcutaneous model. Excitingly, despite the 
fact that NanoLuc/fluorofurimazine emits mostly blue light, we prove that cells trapped in mice lungs vascu-
lature could be visualised via the NanoLuc/fluorofurimazine pair and compare the results to the AkaLuc/Aka-
Lumine system. Therefore, among the tested analogues, fluorofurimazine enables higher substrate loading and 
improved optical imaging sensitivity in small animals, upgrading the use of NanoLuc derived bioluminescent 
systems for deep tissue imaging.   
1. Introduction 
Bioluminescence imaging (BLI) is based on a biochemical reaction 
that is dependent on the oxidation of a luminophore containing sub-
strate (luciferin) by luciferase enzymes with light emission as a result. 
Luciferase enzymes and their substrates are extensively used as effective, 
non-invasive screening tools in diverse research fields and have become 
a prominent method for live-cell visualization. Improving the perfor-
mance of luciferase enzymes, substrates and their mutants for BLI is an 
important part in improving the tool box available for life science 
research [1]. 
Several thousand bioluminescent species are represented by ~700 
genera among which 90% originate from marine organisms [2,3]. Lu-
ciferases from marine luminous organisms primarily utilise as sub-
strates, coelenterazine [2], varguline [3] or analogues of these two. 
Coelenterazine (CTZ) is best-known as the substrate for luciferases 
derived from the sea pansy Renilla reniformis (RLuc), the luminous 
shrimp Oplophorus gracilirostris and the copepod Gaussia princeps (GLuc), 
yielding light with a fast enzymatic turnover and an emission maxima in 
the blue region (450–485 nm) of the visible spectrum. 
NanoLuc (NLuc) is one of the smallest luciferases in size (19 kDa) and 
an important addition to the marine BLI-toolset [4]. Its small size, 
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luminescence superiority and stability easily replaced other luciferases 
where increased sensitivity, fast response dynamics and low background 
auto-luminescence are vital [5]. The NLuc system is coupled with an 
optimized CTZ analogue, the 2-furanylmethyl-deoxycoelenterazine, 
known as furimazine, which when paired with NLuc gives ~2.5 
million-fold brighter luminescence in mammalian cells and ~150-fold 
greater specific activity than firefly (Photinus pyralis) or Renilla lucifer-
ases [4]. 
Furimazine and its analogues are generally lipophilic and their sol-
ubility in aqueous solutions has limited the maximum injectable dose 
into small animals (e.g. 1.3 μmol in a polyethylene glycol (PEG) [6] 
based buffer and 0.016 μmol in Phosphate Buffered Saline (PBS) [7]. 
Therefore, furimazine analogues with improved solubility and 
bioavailability are needed to improve NanoLuc sensitivity for in vivo 
imaging [8]. Moreover, the NanoLuc/furimazine system mainly emits 
blue light, further limiting the sensitivity of detection in deep tissue. 
Many synthetic analogues of CTZ have been reported in recent years, 
mostly focusing on the modification of the C-2, C-5, C-6 and C-8 sub-
stituents of the imidazopyrazinone core [4,9], with the most effort on 
modifying the C-2 and C-6 position [5–7]. The novel analogues were 
mostly optimized in order to improve in vivo imaging with NanoLuc, 
leading to better compound stability and more efficient light penetration 
through tissues [5–7]. A chemical library of 135 CTZ-analogues, the 
imidazo[1,2-a]pyrazin-3-one, have been recently synthetized as stabi-
lized O-acetylated precursors (hikarazines) with an original synthesis 
route [10,11]. Some examples show robust bioluminescent properties in 
terms of signal intensity and duration of the reaction. Particular exam-
ples turned out to be biochemically more efficient than furimazine with 
up to 2.5 increased light intensity and signal stability lasting up to 2 h 
[11]. Novel furimazine analogues, with increased aqueous solubility, 
were recently developed and named hydrofurimazine (HFz) and fluo-
rofurimazine (FFz) [12]. These analogues enable in vivo applications by 
allowing the delivery of higher substrate doses via single intraperitoneal 
injection in mice leading to extended light emission in vivo for NanoLuc 
[13]. 
In the current work we investigated the BLI properties of novel fur-
imazines (HFz and FFz) [11] and 3 different hikarazines (hikarazine- 
001, hikarazine-003 and hikarazine-097) [14–16] by evaluating their in 
vivo performance as substrates for imaging with NanoLuc, as the refer-
ence marine luciferase since recently they have demonstrated to be 
better suited for in cellulo and in vivo NLuc based imaging [14–16]. 
Although the above mentioned NanoLuc substrates have been re-
ported to perform well in vivo, no direct comparison has been performed 
yet. In the present study, we first evaluated 5 recently reported ana-
logues in vitro, through controlled conditions, using cells expressing a 
known amount of NanoLuc reporter, following with an in vivo compar-
ison in a subcutaneous model. Secondly, since BLI in deep tissue is 
mostly dependent on the amount of generated photons and the emission 
wavelength, we tested the best performing NLuc/substrate pairing 
(NLuc/fluorofurimazine) in deep tissue, by imaging transferred biolu-
minescent cells that get entrapped in mice lungs, and compared it to the 
near-infrared AkaLuc/AkaLumine system [17], recently described by 
Iwano et al. 
2. Materials & Methods 
2.1. Cell Propagation for Life Cell Assays 
Human embryonic kidney (HEK-293T) cells were grown in Dulbec-
co’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich), supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were 
cultured in T-175 flasks (Thermo Fisher Scientific) until reaching 
confluence; growth media was aspirated and cells were washed with PBS 
(Sigma-Aldrich). The PBS was aspirated and the cells were removed 
from the flask by the addition of 3 mL of TrypLE™Express Trypsin (Life 
Technologies) and were incubated at 37 ◦C. Cells were centrifuged at 
1500 RPM, washed, re-suspended in 5 mL of fresh growth media, and 
then counted using a BioRad TC20 cell counter. Cells were diluted to a 
desired final concentration and were plated in 96 well plates (Greiner 
Cell Star®) in total volume of 100 μL at 25000 cells/well. The culture 
was incubated at 37 ◦C with 5% CO2. 
2.2. Lentiviral Production 
The plasmids pCDH-EF1-NanoLuc-T2A-copGFP and pCDH-EF1- 
AkaLuc-T2A-copGFP were engineered by NanoLuc or AkaLuc lucif-
erase gene insertion into the vector backbone pCDH-EF1-T2A-copGFP. 
The inserted NanoLuc/AkaLuc luciferase genes were amplified with 
specific primers from pCDH-EF1-NanoLuc plasmid (Promega)/pcDNA3 
Venus-AkaLuc plasmid (Riken BRC Repository) without a stop codon 
using BamHI and NotI sites into the cut vector: pCDH-EF1-MCS-T2A- 
copGFP. The pCDH-EF1-NanoLuc-copGFP/pCDH-EF1-AkaLuc-T2A- 
copGFP lentivirus were constructed using methods already described 
earlier in literature [18,19]. Virus production and cell transduction were 
performed under appropriate biosafety level conditions (ML-II) in 
accordance with the National Biosafety Guidelines and Regulations for 
Research on Genetically Modified Organisms. Procedures and protocols 
were reviewed and approved by the EMC Biosafety Committee (GMO 
permit 99-163). 
Lentiviral particles were produced by transfection of HEK-293T 
packaging cells with three packaging plasmids (pCMV-VSVG, pMDLg- 
RRE (gag-pol), pRSV-REV) (Addgene) and the lentiviral vector 
plasmid using PEI transfection reagent (1 mg/mL)/μg DNA. The super-
natant, containing lentiviral particles was collected after 48 h and 72 h. 
Viral quantification was performed using the standard antigen-capture 
HIV p24 ELISA (ZeptoMetrix). 
2.3. Generation of Luciferase-Expressing HEK-293T Cell Lines 
HEK-293T cells were grown in culture dishes to 50% confluency in 
culture medium and were infected with a lenti-viral stock, resulting in 
NanoLuc or AkaLuc expression, depending on the used lentivirus. Cells 
were transduced with MOI 1 of pCDH-EF1-NanoLuc-T2A-copGFP/ 
pCDH-EF1-AkaLuc-T2A-copGFP lentivirus plus with polybrine (hex-
ametride bromide) (Sigma-Aldrich) at the final concentration of 8 μg/ 
mL. Cells were sorted for GFP expression using FACS (BD-FACS AriaIII, 
BD Biosciences). Transgene expression was confirmed by the presence of 
the green fluorescent protein copGFP (excitation/emission maximum =
475/509 nm). Stably transduced cells (HEK-293T-EF1-NanoLuc-T2A- 
copGFP/HEK293T-EF1-AkaLuc-T2A-copGFP) were further cultured and 
expanded and have been used later for all experiments regarding mea-
surement of photon production when using different furimazine 
analogues. 
2.4. In Vitro Cell-Based Imaging 
HEK-293T-NanoLuc cells were seeded in a 96-well black plate 
(Greiner Cell Star®) at a density of 25 000 cells per well. Post 24 h, cells 
were washed in PBS and imaged at the IVIS Imager (PerkinElmer) after 
addition of 6 different substrates profiled within this study; furimazine, 
hydrofurimazine (HFz), fluorofurimazine (FFz), all three provided by 
Promega and the hikarazine-001, hikarazine-003 and hikarazine-097 
provided by Institute Pasteur, Paris, France. The hikarazines (hikar-
azine-001, hikarazine-003, hikarazine-097) were dissolved (1 mg) in a 
mixture of 0,2 mL DMSO (Sigma-Aldrich) and then diluted in a solution 
of 0,3 mL of acidic ethanol made from addition of 37% hydrochloric acid 
(Sigma-Aldrich), 100 μL on 12 mL of 100% ethanol (Sigma-Aldrich) to 
give a stock solution of 1 mg/mL which was then incubated at 50 ◦C for 
2 h. Furimazine, hydrofurimazine (HFz) and flurofurimazine (FFz) were 
dissolved in 100% ethanol to give a 5 mM stock solution. All of the 
substrates were further diluted in DMEM medium to a final concentra-
tion of 10 μM (100 μL/well). Bioluminescence signal from wells was 
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measured at the IVIS (Perkin Elmer) spectrum system every 5 min after 
substrate addition. All in vitro cell-based measurements were acquired 
after 1 min at 37 ◦C using a 30 s acquisition time with an open filter. 
Experiments were performed in triplicates and were repeated three 
times. Data was analyzed using Living Image 4.3 software (Perkin 
Elmer) by applying the appropriate region of interest (ROI). 
As for the once-cell assay; HEK-293T-NanoLuc cells were plated in a 
black 96-well plate in seven dilutions starting at a density of approxi-
mately 100 cells per well as the starting cell-concentration. Further cell- 
dilutions were carried out with a ½ ratio; (50, 25, 12, 6, 3, 1, 0) cells per 
well. Luminescence images were acquired with the GloMax® Microplate 
Reader (Promega) immediately after substrates addition; furimazine, 
hydrofurimazine (HFz), fluorofurimazine (FFz), hikarazine-001, hikar-
azine-003 and hikarazine-097 with a final concentration of each sub-
strate of 10 μM. For measurement of total luminescence, we used 1 s of 
integration time. Measurements were performed at room temperature 
18–20 ◦C. Experiments were performed in triplicates and were repeated 
three times. All data were plotted using GraphPad Prism. 
2.5. Substrate Formulation for Use in Whole-Animal Imaging 
The hikarazines (hikarazine-001, hikarazine-003, hikarazine-097) 
(Institute Pasteur, Paris, France) were dissolved (1 mg) in a mixture of 
0.2 mL DMSO (Sigma-Aldrich) and then diluted in a solution of 0.3 mL of 
acidic ethanol made from addition of 37% hydrochloric acid (Sigma- 
Aldrich), 100 μL on 12 mL of 100% ethanol (Sigma) to give a stock so-
lution of 1 mg/mL which was then incubated at 50 ◦C for 2 h. The stock 
solution was then dissolved in PBS at a final concentration of 333 nmol 
in 100 μL. Furimazine, hydrofurimazine (HFz) and fluorofurimazine 
(FFz) (Promega), powder formulations for intravenous administration, 
were dissolved in 100% ethanol to give a 5 mM stock solution. The stock 
solution was then dissolved in PBS to a final dose of 333 nmol in 100 μL. 
Stock aliquots of the poloxamer-407 HFz and FFz, for the intraperitoneal 
administration, were prepared by the addition of 480 μL of PBS to the 
vial and vortexed to create a plain solution resulting in a single injection 
dose of 12 mg poloxamer-407 and 4.3 μmol HFz and FFz, and 1.3 μmol 
(145 μL). 
AkaLumine (Sigma-Aldrich) was dissolved in PBS to a concentration 
of 33 mM (around 3 μmol/100 μL) for i.p. injection. These doses were 
chosen considering maximum solubility and tolerability in mice and 
maximum attainable signal based on previous findings. 
2.6. In Vivo Bioluminescence Imaging of Subcutaneously Implanted 
NanoLuc Expressing Cells 
Animal experiments were approved by the Bioethics Committee of 
Erasmus MC, Rotterdam, The Netherlands and performed in accordance 
with national guidelines and regulations established by the Dutch Ex-
periments on Animal Act (WoD) and by the European Directive on the 
Protection of Animals used for scientific purpose (2010/63/EU). BALB/c 
nude (males) were obtained from Charles River Laboratory (The 
Netherlands). All mice aged 8 weeks were provided access to food and 
water ad libitum and were hosted in the animal facility at the Erasmus 
MC, Rotterdam, The Netherlands. 
For the background assessment mice (n = 3 mice per tested 
analogue) were injected intraperitoneal (i.p.) with the following ana-
logues; 4.3 μmol (in 480 μL PBS) and 1.3 μmol (in 145 μL PBS) of FFz; 
333 nmol of furimazine and hikarazine-003, both in 100 μL of PBS and 3 
μmol of AkaLumine (Sigma-Aldrich) in 100 μL of PBS. Mice were 
anesthetized with isoflurane (1.5%) and imaged 10 min post substrate 
administration at the IVIS Spectrum (PerkinElmer). Supine and prone 
BLI images were acquired at the IVIS, exposure time 1 min. 
For the subcutaneous skin model experiments, 8–10 week old BALB/ 
c nude (males) mice received a subcutaneous injection of 1 × 106 HEK- 
293T-NanoLuc which were prepared in PBS (Sigma-Aldrich) and 
matrigel (Corning) solution (50:50 ratio) in a final injectable volume of 
50 μL. Mice received an injection of 100 μL of the different substrate 
intravenously (n = 6 mice per group) or intraperitoneally (480 μL) (n = 3 
mice per group) right after implantation of cells. The size of the group 
was determined using power analysis. Mice were kept under isoflurane 
anaesthesia (1.5%) and a series of images were taken using an IVIS 
Spectrum with open filter binning = medium, field of view = 12.9 ×
12.9 cm, f/stop = 1 and 1 s exposure time every 5 min for half an hour. 
Data analysis was performed by drawing ROIs in the images taken at the 
peak of bioluminescence emission. 
2.7. In Vivo BLI Comparison of HEK-293T Cells Trapped in the Mouse 
Lung (NLuc/Fluorofurimazine vs. AkaLuc/AkaLumine) 
BALB/c nude (males) were used for the experimental purposes. Post 
cell selection at the flow-cytometry, either HEK-293T-AkaLuc or HEK- 
293T-NanoLuc cells were re-suspended and aliquoted (500000 cells/ 
100 μL) each, and injected into the tail vein of mice. 
10 to 15 min after the cell infusion, the mice were anesthetized with 
1.5% isoflurane for induction and administered via intraperitoneal in-
jection with the respective substrate (100 μL of 3 μmol AkaLumine, 145 
μL of 1.3 μmol fluorofurimazine (FFz). 10 min post substrate adminis-
tration, dorsal BLI images were taken with 1,5% isoflurane and using the 
IVIS Spectrum (PerkinElmer) with following acquisition conditions: 
open for total bioluminescence, exposure time = 1 min, binning = me-
dium: 4, field of view = 12.5 × 12.5 cm, and f/stop = 1. Analysis of BLI 
images was performed with Living Image 4.3 software (PerkinElmer). 
2.8. Statistical Analysis 
For experiments where more than two groups were compared, one- 
way ANOVA, followed by Tukey’s t-test was used to determine signifi-
cant differences among treated groups. 
3. Results 
3.1. In Vitro Performance Comparison of Novel Analogues Paired with 
NanoLuc Luciferase 
Bioluminescence properties of the chosen furimazine analogues 
(Fig. 1), profiled with NLuc were assessed in live HEK-293T cells that 
were stably expressing NLuc luciferase in order to determine the best- 
performing NLuc/analogue pairs for in vivo testing. Cells were treated 
with substrates at a final concentration of 10 μM each and imaged in the 
IVIS imager at 5 min intervals after substrate administration for half an 
hour (Fig. 2a). 
The imaging results in live cells showed brighter signals with the 
hikarazines (hikarazine-001, hikarazine-003 and hikarazine-097) than 
furimazine and its analogues hydrofurimazine (HFz) and fluorofur-
imazine (FFz) (Fig. 2b). We found that peak light emission was highest 
with hikarazine-003, followed by hikarazine-001, hikarazine-097 and 
fluorofurimazine. The signal of all tested analogues proved to be 
extended and stable over the 30 min imaging duration. 
We evaluated the correlation between reporter signal and number of 
cells, by plating a decreasing number of cells, ranging from 100 to 1 cell 
per well. Linear correlation was found and detection of single cells was 
achieved with all tested analogues. Again, the hikarazines showed to be 
brighter: hikarazine-003 = 2.75e+004 rlu/cell; hikarazine-001 =
2.48e+004 rlu/cell; hikarazine-097 = 2.16e+004 rlu/cell to the novel 
furimazine analogues and to furimazine itself: furimazine = 1.42e+004 
rlu/cell; hydrofurimazine = 1.07e+004 rlu/cell and fluorofurimazine =
2.32e+004 rlu/cell (Fig. 2c). 
Since the photon emission was comparable among the 3 tested 
hikarazines, we selected the brightest analogue (hikarazine-003) for 
further in vivo evaluation among with fluorofurimazine (FFz). 
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3.2. In Vivo Bioluminescence Imaging of Subcutaneously Implanted Cells 
Prior to testing the compounds in mice, we assessed background 
emission of all substrates, including the AkaLuc substrate, AkaLumine, 
in nude mice not expressing a luciferase reporter. We administered the 
substrates intraperitoneally, allowing us to estimate autoluminescence 
in the absence of reporter enzymes (NanoLuc/AkaLuc). All substrates 
were administered with the doses recommended by the literature as 
appropriate for each substrate. Negligible signals were detected with 
AkaLumine, whereas all tested NLuc analogues gave background signal 
of around 102 ph/s in the abdomen in nude mice (Supplementary Fig. 1). 
Given their intense in vitro brightness, we selected FFz and 
hikarazine-003 for further in vivo evaluation. Each substrate was 
administered via intravenous (i.v.) and intraperitoneal (i.p.) injection in 
mice. Around 1 × 106 HEK-293T cells were transferred in nude mice and 
injected subcutaneously in the lower flank, stably expressing NanoLuc 
luciferase. 
For the i.v. administration route, the images were acquired after tail 
vein injection of equimolar substrate doses (injection volume 100 μL); 
fluorofurimazine (333 nmol) (Fig. 3a), furimazine (333 nmol) (Fig. 3b) 
and hikarazine-003 (333 nmol) (Fig. 3c). The results demonstrated that 
the NanoLuc/fluorofurimazine pair was significantly brighter (around 
8.6 fold) than the NanoLuc/furimazine pair and around 11.62 fold 
higher than the NanoLuc/hikarazine/003 pair (Fig. 3d) when adminis-
tered i.v. at equimolar doses. The signal with the NanoLuc/fluorofur-
imazine pair showed a very high photon emission for the whole 30 min 
of acquisition, with an average of 3.58E+09 ph/s and an initial lumi-
nescence (1 min post injection) of 1.70E+10 (Fig. 3d). 
We further evaluated the BLI emission when administering the an-
alogues i.p. We tested the newly formulated fluorofurimazine (FFz) in 3 
different ways; with a dose of 4.3 μmol (Fig. 4a) and 333 nmol derived 
from the solubilised poloxamer-P407 cake formulations [11] (Fig. 4c), 
and with fluorofurimazine derived stock powder formulation (333 
nmol) (Fig. 4b). Hikarazine-003 and furimazine were administered with 
a final concentration of 333 nmol (Fig. 4d and e). 
As shown in Fig. 5 the 4.3 μmol NanoLuc/fluorofurimazine pair 
showed excellent BLI properties with a very high, sustained signal of an 
average of 1.22E+10 ph/s, around 11 fold higher than the reference 
333 nmol NanoLuc/furimazine pair and 3 fold higher than the 333 nmol 
NanoLuc/hikarazine-003 combination. The fluorinated FFz (333 nmol; 
4.3 μmol) and its powder stock formulation (333 nmol) generated 3-fold 
brighter signal than hikarazine-003 (Fig. 5). 
3.3. In Vivo Deep Tissue BLI: NLuc/Fluorofurimazine vs. AkaLuc/ 
AkaLumine 
To assess how well NLuc in combination with FFz performs in deep 
tissue, we evaluated the brightness from HEK-293T cells stably 
expressing NanoLuc and copGFP, and compared it to photon emission of 
cells expressing AkaLuc and copGFP. We used GFP to ensure equimolar 
expression of both bioluminescent enzymes. The luciferase expressing 
cells were localised in mice lungs after tail vein injection of approxi-
mately 5 × 105 HEK-293T expressing either NLuc-copGFP or AkaLuc- 
copGFP [20,21] (Fig. 6a). A dose of 4.3 μmol FFz gives more light, but 
was found to cause weight loss and was associated with organ damage in 
mice: later on, a dose was established which showed no toxicity in mice 
consisting of 1.3 μmol FFz in P-407 [12], which we implemented in this 
experiment. Mice were imaged 10 min after cell administration and a 
kinetic analysis was performed after i.p. injection of substrate (1.3 
μmol/145 μL FFz; 3 μmol/100 μL AkaLumine) for 30 min. We were able 
to detect signals from both luciferase systems with a 1.5-fold higher 
photon emission arising from the AkaLuc/AkaLumine system (Fig. 6b). 
For the emission comparison, values at the time point of peak emission 
were used. The signals were corrected by a factor of 2.3 fold, given the 
higher-level of GFP expression of HEK-293T-AkaLuc expressing cells, 
determined prior the imaging session. 
4. Discussion 
In the present study we tested novel furimazine analogues paired 
with NanoLuc luciferase to determine the most optimal NLuc/luciferin 
pair for in vivo imaging. We report on photon yields of two novel, fur-
imazine analogues, recently published by Su, Y. et al., named hydro-
furimazine (HFz) and fluorofurimazine (FFz) and three different O- 
acetylated furimazine analogue derivates [9], known as ‘hikarazines’ 
(hikarazine-001, hikarazine-003 and hikarazine-097) and we confirm 
that many of these novel analogues improve the efficient brightness of 
NanoLuc in vitro and in vivo. 
Our aim was to compare the best performing analogues in an in vivo 
setting based on different routes of administration. The comparison of 
Fig. 1. Chemical structures of furimazine analogues in this article; hikarazine-001, hikarazine-003, hikarazine-097, hydrofurimazine (HFz), fluorofurimazine (FFz) 
and furimazine. 
N. Gaspar et al.                                                                                                                                                                                                                                 
Journal of Photochemistry & Photobiology, B: Biology 216 (2021) 112128
5
Fig. 2. In cellulo performance of novel furimazine analogues in live HEK-293T cells transiently expressing NanoLuc luciferase. (a) Bioluminescence (BLI) imaging of 
substrates profiled with NanoLuc luciferase expressing cells. (b) Comparison of BLI-intensities of tested furimazine derivatives at a 10 μM concentration. BLI spectra 
were obtained at the IVIS Imager in triplicates, acquisition time of 1 s. Statistical analysis of triplicates was performed using ONE-Way Anova followed by Tukey’s t- 
test (p value < 0.001). (c) Comparison of bioluminescence intensities of the substrates in HEK-293T cells expressing NanoLuc luciferase (NLuc) at various cell- 
concentrations. Luminescence images were acquired with the GloMax® Microplate Reader (Promega) immediately after substrates addition (10 μM), 1 s integra-
tion time. 
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Fig. 3. In vivo imaging of fluorofurimazine, hikarazine-003 and furimazine at 333 nmol after intravenous (i.v) administration in a subcutaneous mice model. In vivo 
imaging after (i.v.) administration (n = 6) of; (a) fluorofurimazine; (b) furimazine and (c) hikarazine-003. (d) Quantification of total maximum flux of fluorofur-
imazine, hikarazine-003 and furimazine at 333 nmol after intravenous administration. Spectral data was acquired for 30 min, every 5 min after substrate admin-
istration. Imaging data was collected at the IVIS Imager for 30 min using open filters and an exposure time of 1 s. 
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Fig. 4. In vivo imaging of fluorofurimazine, 
hikarazine-003 and furimazine at different 
concentrations after intraperitoneal (i.p.) 
administration in a subcutaneous mice 
model. In vivo imaging after i.p. adminis-
tration of (n = 3); (a) fluorofurimazine-P407 
formulation (4.3 μmol); (b) fluorofurimazine 
powder stock formulation (333 nmol); (c) 
fluorofurimazine-P407 formulation (333 
nmol); (d) furimazine (333 nmol) and (e) 
hikarazine-003 (333 nmol). Spectral data 
was acquired for 30 min, every 5 min after 
substrate administration using open filters 
and an exposure time of 1 s.   
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BLI systems using cells expressing a known amount of luciferase injected 
subcutaneously in animals has been largely used in the past [22–25]. As 
for coelenterazine based substrates, it is generally known that they 
produce higher light output when injected intravenously [26]. Yet for 
repeated measurements, intraperitoneal in vivo injections should be 
preferred, given the reproducibility of the technique being less prone to 
misinjections. 
A recent study reported that furimazine possibly displays toxic side 
effects, when administered repeatedly in small animals with doses 
exceeding 40 μg of substrate per day [27]. Furimazine, inter alia, is 
poorly soluble in aqueous solution, whereas D-luciferin salt can be dis-
solved to high concentrations in simple buffered saline [12,28], and 
repeatedly administered via intraperitoneal administration (i.p.). The 
preferred furimazine administration route is via intravenous (i.v.) in-
jection, since higher photon emission is achieved. However, signals 
appear faster after substrate injection and show a rapidly decaying ki-
netic, limiting its use in certain areas of molecular imaging where a 
broader imaging window (longer substrate half-life) is required [13]. 
Based on our in vivo results we can clearly highlight on the impor-
tance of substrate solubility and bioavailability as the number one lim-
itation for sensitive in vivo bioluminescent imaging [12]. The pairs, 
NanoLuc/fluorofurimazine (4.3 μmol and 333 nmol) and NanoLuc/ 
hikarazine-003 (333 nmol), independent of the administration route, 
exhibited brighter (8 or 11-fold) in vivo BLI signals, than the standard 
NanoLuc/furimazine (333 nmol) pair. Moreover, it was clearly evident 
that the NanoLuc/fluorofurimazine (4.3 μmol and 333 nmol) pair was 
11 or 3-fold brighter when administered intravenously or intraperito-
neally, compared to the NLuc/hikarazine-003 pair (333 nmol). The 
photon generation from FFz is more prolonged and more intense, 
allowing in vivo tracking with the NLuc reporter over long time periods. 
We also address in vivo coelenterazine analogues autoluminescence17 
by simply injecting the analogues in mice without the luciferase reporter 
being expressed. Such an approach provides accurate insight whether 
the compounds are prone to spontaneous light emission. Since dying 
cells expressing the NanoLuc reporter release the active luciferase in the 
bloodstream, which does not require any cofactors, and therefore can 
catalyze oxidation of its substrates and give background light. Our re-
sults demonstrate that NLuc substrate analogues (FFz, hikarazine-003) 
and furimazine itself also spontaneously oxidase, without the reporter 
being present in nude mice, and produce detectable light emission. This 
is important to take into account when performing imaging with fur-
imazine and coelenterazine based analogues; performing a pre-scan and 
the proper positioning of animals is highly recommended in order to 
obtain accurate experimental results [12]. 
We next assessed the in vivo BLI performance of FFz with NLuc in 
deep tissue (lungs) and compared it to the near infra-red emission of 
Fig. 5. Signal quantification after intraperitoneal (i.p.) administration of fluorofurimazine, hikarazine-003 and furimazine at different concentrations. Fluorofur-
imazine (333 nmol and 4.3 μmol)-P407 formulation and FFz (333 nmol) from the powder stock formulation showed significantly higher photon emission in vivo than 
furimazne and hikarazine-003 (p value < 0.0001). 
Fig. 6. Bioluminescent signal detection from a minuscule number of AkaLuc- and NanoLuc-expressing cells trapped in mice lung vasculature. Performance com-
parison of AkaLuc/AkaLumine versus NanoLuc/fluorofurimazine. (a) Bioluminescent imaging of mice intravenously injected with 105 HEK-293T cells expressing 
NanoLuc (right) with fluorofurimazine and (a) HEK-293T cells expressing AkaLuc (left) with AkaLumine. Substrates were administered 10 min post cell adminis-
tration via an intraperitoneal injection; the animals were injected with 3 μmol AkaLumine and 1.3 μmol of fluorofurimazine. (b) Data was collected at the IVIS (1 s 
exposure time) and are presented as ±SD of n = 3 mice per substrate analogue. 
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AkaLuc/AkaLumine pair, as a near-infrared BLI system reference with 
an emission peak at 650 nm.The luciferase expression was localised in 
mice lung vasculature by tail vein injection of NLuc and AkaLuc 
expressing cells [20,21]. AkaLuc/AkaLumine, yielded a 1.5-fold higher 
signal then FFz with NLuc. Nevertheless, here we demonstrate clearly 
that NLuc can be used for deep tissue imaging in small animals, when 
combined with the novel FFz. 
Multiple BL reporters are derived from NLuc luciferase that uses 
furimazine, or its analogues as substrates, like Antares [6] Antares 2 and 
LumiScarlet [24,29]. These protein fusions exhibit emission wave-
lengths above 600 nm due to intramolecular bioluminescence resonance 
energy transfer (BRET), and therefore transmit light more easily through 
mammalian tissues. Moreover, using a different strategy, furimazine 
analogues can generate red-shifted emission when paired with NanoLuc 
[30,31], and therefore could enable more sensitive visualization in deep 
tissue. However, all of these bioluminescent systems do not show peak of 
emission in the near infrared region as the AkaLuc/AkaLumine system. 
In conclusion, the combination of superior brightness and signal 
duration, given by FFz, enables bioluminescence imaging with NanoLuc 
luciferase, in superficial and deep tissue, making it applicable for 
studying diverse physiological events over a substantial period of time. 
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